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Major Depression is the most frequent mood disorder, with a lifetime prevalence 
that has been reported to range from 7% to 21%. It is associated with a 
substantial functional impairment, diminished quality of life, increased burden 
both for patients and caregivers, as well as with a higher risk of mortality.  
Although the underlying mechanisms have not yet been clearly defined in the 
last decade the importance of the role of neuropeptides, including Galanin 
(GAL) and the N-terminal fragment GAL(1-15) and/or their receptors in the 
treatment of stress-related mood disorders is becoming increasingly apparent.   
We have described that GAL(1-15) induces strong depression-related and 
anxiogenic-like effects in rats and these effects were significantly stronger than 
the ones induced by GAL. The GALR1-GALR2 heteroreceptor complexes in the 
dorsal hippocampus and dorsal raphe (DR) were involved in these effects and 
demonstrated also in cellular models. 
Although several neurotransmitter systems and brain areas have been 
implicated in depression, the pharmacological treatment of major depression is 
mainly based on drugs elevating serotonergic (5-HT) activity. Specifically, 
selective 5-HT reuptake inhibitors (SRRIs) are the most commonly used for 
treatment of major depression. In particular, Fluoxetine (FLX) is usually chosen 
for the treatment of symptoms of depression 
In view of these results the purpose of the current study was to assess the 
ability of GAL(1–15) to modulate the behavioral effects of the 5-HT1AR agonist 
8-OH-DPAT and FLX. 
 
We have analyzed the effect of GAL (1–15) on the 5-HT1AR agonist 8-OH-
DPAT and FLX-mediated responses in a behavioral test of depression. We 
tested the involvement of GALR using an in vivo of siRNA GALR1 or siRNA 
GALR2 knockdown rats. Moreover, to study wether the effects of GAL(1–15) on 
FLX action were mediated via 5-HT1AR, we have analyzed the effect of the 5-
HT1AR antagonist WAY100635 in the GAL(1-15)-mediated effect in the FST. 
We have also determined the binding characteristics and mRNA levels of 5-
HT1AR in the DR and dorsal hippocampus after GAL(1-15)-FLX administration.  
 
 
GAL(1-15) enhances the antidepressant-like effects induced by the 5-HT1AR 
agonist 8-OH-DPAT or FLX  in the forced swimming test (FST), and we 
demonstrate the involvement of GALR1/GALR2 heteroreceptor complex in the 
GAL(1-15)-mediated effect using in vivo rat models for siRNA GALR1 or GALR2 
knockdown. The results on the proximity ligation assay (PLA) suggest the 
existence of GALR1-GALR2-5-HT1AR heteroreceptor complexes since positive 
PLA were obtained for both GALR1-5-HT1AR and GALR2-5-HT1AR complexes 
in the DR and hippocampus.  
Importantly, 5-HT1A receptors (5HT1AR) also participate in the GAL(1-15)/FLX 
interactions since the 5HT1AR antagonist WAY100635 blocked the behavioral 
effects in the FST induced by the coadministration of GAL(1-15) and FLX. The 
mechanism underlying GAL(1-15)/FLX interactions affected the binding 
characteristics as well as the mRNA levels of 5-HT1AR specifically in the dorsal 
hippocampus. 
 
The results open up the possibility to use GAL(1-15) as for a combination 
therapy with FLX for treatment of depression and to develop novel drugs 
specifically targeting GALR1-GALR2-5-HT1AR heteroreceptor complexes 
complexes as a novel strategy for treatment of depression. 
 
